News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
213,800 Results
Type
Article (12083)
Company Profile (17)
Press Release (201699)
Multimedia
Podcasts (23)
Webinars (7)
Section
Business (69470)
Career Advice (678)
Deals (12655)
Drug Delivery (32)
Drug Development (26101)
Employer Resources (52)
FDA (4939)
Job Trends (4724)
News (102643)
Policy (9221)
Tag
2027 BioCapital Standard (3)
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Pharm Country Standard (2)
40 Under 40 (1)
Academia (1121)
Academic (1)
Accelerated approval (20)
ADA (11)
Allergies (84)
Alliances (19235)
ALS (109)
Alzheimer's disease (697)
Antibody-drug conjugate (ADC) (304)
Approvals (5363)
Artificial intelligence (364)
ASCO (114)
Autoimmune disease (180)
Automation (25)
Bankruptcy (52)
Belgium (3)
Best Places to Work (4027)
BIO (24)
Biologics (14)
BIOSECURE Act (1)
Biosimilars (145)
BioSpace Insights (50)
Biotechnology (15)
Bispecific (12)
Bladder cancer (69)
Brain cancer (29)
Breast cancer (278)
Cancer (2535)
Cardiovascular disease (190)
Career advice (593)
Career pathing (22)
CAR-T (116)
CDC (13)
CDMO (65)
Celiac Disease (1)
Cell-line development (1)
Cell therapy (349)
Cervical cancer (21)
Clinical research (23065)
Collaboration (1188)
Commercialization (20)
Company closure (3)
Compensation (71)
Complete response letters (15)
COVID-19 (2026)
CRISPR (63)
C-suite (569)
Cystic fibrosis (61)
Data (3472)
Decentralized trials (1)
Denatured (20)
Depression (64)
Dermatology (82)
Diabetes (194)
Diagnostics (2581)
Digital health (28)
Diversity (7)
Diversity, equity & inclusion (15)
Drug discovery (220)
Drug pricing (35)
Drug shortages (1)
Duchenne muscular dystrophy (93)
Earnings (17917)
Editorial (9)
Employer branding (6)
Employer resources (55)
Events (27187)
Executive appointments (470)
Eye disease (2)
FDA (6534)
Fibrodysplasia Ossificans Progressiva (7)
Fragile X (1)
Friedreich's ataxia (6)
Frontotemporal dementia (19)
Funding (1043)
Gene editing (115)
Generative AI (32)
Gene therapy (223)
GLP-1 (341)
Government (1389)
Grass and pollen (4)
Guidances (128)
Healthcare (5716)
Hematology (68)
HIV (47)
Huntington's disease (17)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (55)
Immunology and inflammation (92)
Immuno-oncology (57)
Indications (96)
Infectious disease (2157)
Inflammatory bowel disease (90)
Inflation Reduction Act (7)
Influenza (71)
Intellectual property (117)
Interviews (129)
IPO (6176)
IRA (14)
Job creations (836)
Job search strategy (463)
JPM (13)
Kidney cancer (6)
Kidney disease (45)
Labor market (29)
Layoffs (99)
Leadership (22)
Legal (2064)
Licensing (33)
Liver cancer (45)
Longevity (22)
Lung cancer (347)
Lung diease (4)
Lymphoma (212)
Machine learning (20)
Management (21)
Manufacturing (421)
Marketing (6)
MASH (57)
Medical device (3917)
Medtech (3994)
Mergers & acquisitions (7166)
Metabolic disorders (473)
mRNA (120)
Multiple sclerosis (66)
Multispecific (2)
NASH (1)
Netherlands (8)
Neurodegenerative disease (184)
Neuropsychiatric disorders (32)
Neuroscience (1355)
Neurotech (1)
NextGen: Class of 2026 (1895)
Non-profit (1294)
Now hiring (5)
Obesity (215)
Opinion (68)
Ovarian cancer (91)
Pain (81)
Pancreatic cancer (123)
Parkinson's disease (181)
Partnered (12)
Patents (202)
Patient advocacy (2)
Patient recruitment (314)
Patient selection (25)
Peanut (17)
People (20885)
Peptides (11)
Pharmaceutical (6)
Pharmacy benefit managers (9)
Phase 1 (6792)
Phase 2 (9746)
Phase 3 (8743)
Pipeline (4444)
Policy (59)
Postmarket research (783)
Preclinical (2832)
Press Release (20)
Prostate cancer (113)
Psychedelics (15)
Radioligand (1)
Radiopharmaceuticals (99)
Rare diseases (361)
Real estate (1514)
Recruiting (22)
Regenerative medicine (8)
Regulatory (7905)
Reports (14)
Research institute (999)
Resumes & cover letters (84)
Rett syndrome (10)
RNA editing (10)
RSV (28)
Schizophrenia (62)
Series A (240)
Series B (182)
Service/supplier (2)
Sickle cell disease (20)
Special edition (4)
Spinal muscular atrophy (29)
Sponsored (14)
Startups (1776)
Stem cells (1)
Stomach cancer (4)
Substance use disorders (6)
Supply chain (40)
Tariffs (4)
The Weekly (3)
Vaccines (520)
Venture capital (52)
Weight loss (85)
Wet AMD (1)
Women's health (63)
Worklife (14)
Date
Last 7 days (187)
Last 30 days (826)
Last 365 days (9709)
2026 (7679)
2025 (9182)
2024 (10817)
2023 (12760)
2022 (18917)
2021 (20835)
2020 (20198)
2019 (14048)
2018 (10589)
2017 (9956)
2016 (9140)
2015 (11069)
2014 (8000)
2013 (6400)
2012 (6453)
2011 (6727)
2010 (5799)
Location
Africa (249)
Alabama (42)
Alaska (4)
Arizona (76)
Arkansas (5)
Asia (28579)
Australia (3557)
California (4569)
Canada (1351)
China (940)
Colorado (298)
Connecticut (238)
Delaware (171)
Europe (33935)
Florida (601)
Georgia (77)
Hawaii (2)
Idaho (21)
Illinois (306)
India (81)
Indiana (163)
Iowa (11)
Japan (508)
Kansas (28)
Kentucky (11)
Louisiana (15)
Maine (13)
Maryland (471)
Massachusetts (3370)
Michigan (49)
Minnesota (193)
Mississippi (5)
Missouri (30)
Montana (7)
Nebraska (6)
Nevada (47)
New Hampshire (25)
New Jersey (1504)
New Mexico (8)
New York (1401)
North Carolina (458)
North Dakota (6)
Northern California (2498)
Ohio (123)
Oklahoma (10)
Oregon (19)
Pennsylvania (776)
Puerto Rico (5)
Rhode Island (13)
South America (276)
South Carolina (10)
South Dakota (1)
Southern California (1677)
Tennessee (55)
Texas (517)
United States (15829)
Utah (155)
Vermont (2)
Virginia (156)
Washington D.C. (29)
Washington State (421)
West Virginia (2)
Wisconsin (52)
Wyoming (4)
213,800 Results for "nippon shinyaku co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
July 30, 2026
·
5 min read
Press Releases
NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital
June 23, 2026
·
1 min read
Press Releases
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
June 26, 2026
·
2 min read
Press Releases
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
June 26, 2026
·
2 min read
Business
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.
April 4, 2024
·
3 min read
Press Releases
Visionary Holdings’ Subsidiary Nanjing Tuoyuanjian Health Technology Co., Ltd. Enters into Distribution Agreement with Suncare (Shanghai) Health Technology Co., Ltd.
Collaboration Expected to Expand the Commercialization of Stem Cell Aesthetic and Anti-Aging Products Through an AI-Enabled Community Healthcare and Senior Care Network in China
July 29, 2026
·
4 min read
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
Vicore Pharma Holding AB, unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, announced it has entered into an exclusive licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company, to develop and commercialize Vicore’s drug candidate C21 in Japan.
February 9, 2024
·
4 min read
Gene therapy
Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku
In exchange for its investigational gene therapies, Regenxbio will receive $110 million upfront and up to $700 million in milestones. After hitting an all-time low of $6.95 at close of business yesterday, the stock surged on the news by nearly 20% before markets opened Tuesday.
January 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
July 17, 2026
·
4 min read
Press Releases
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
January 27, 2025
·
5 min read
1 of 21,380
Next
